Get the Stockscreener App
12.93
1.17%
0.15
After Hours:
12.92
-0.010
-0.08%
Eyepoint Inc stock is traded at $12.93, with a volume of 783.85K.
It is up +1.17% in the last 24 hours and down -9.20% over the past month.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
See More
Previous Close:
$12.78
Open:
$12.87
24h Volume:
783.85K
Relative Volume:
0.73
Market Cap:
$1.08B
Revenue:
$31.37M
Net Income/Loss:
$-231.96M
P/E Ratio:
-4.0876
EPS:
-3.1632
Net Cash Flow:
$-243.39M
1W Performance:
+4.70%
1M Performance:
-9.20%
6M Performance:
-5.48%
1Y Performance:
+130.89%
1-Day Range:
$12.72
$13.43
1-Week Range:
$11.40
$13.43
52-Week Range:
$5.455
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Name
Eyepoint Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
12.93 | 1.07B | 31.37M | -231.96M | -243.39M | -3.1632 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Inc Stock (EYPT) Latest News
(EYPT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets - Yahoo Finance
EyePoint Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
EyePoint lines up Goldman Sachs, Jefferies, Stifel fireside chats - Stock Titan
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Should I Buy EYPT (EyePoint Pharmaceuticals, Inc.) | AI Analysis, Technical & News Insights - Kavout
EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards | EYPT Stock News - Quiver Quantitative
Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness - Yahoo Finance
[SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - Sahm
EyePoint’s DURAVYU Receives Third Consecutive Positive DSMC Review for Wet AMD - The Clinical Trial Vanguard
EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review - Moomoo
EyePoint (EYPT) Receives Positive Review for Duravyu Trials - GuruFocus
EyePoint Pharmaceuticals stock (US30233B1098): Phase 3 trials clear third safety review - AD HOC NEWS
EyePoint Announces Third Positive DSMC Review for DURAVYU Phase 3 Wet AMD Trials, Topline Data Expected Mid-2026 - Minichart
EyePoint's late-stage eye drug trials to continue after safety panel review - TradingView
EyePoint’s wet AMD trial continues after safety review By Investing.com - Investing.com Australia
Eyepoint announces third consecutive positive DSMC recommendation for phase 3 wet AMD trials for Duravyu(TM), building confidence ahead of mid-2026 topline data - marketscreener.com
EyePoint Advances DURAVYU Phase 3 Wet AMD Program - TipRanks
EyePoint’s wet AMD trial continues after safety review - Investing.com India
EyePoint receives third positive DSMC review; Phase 3 topline data on track for mid-2026 - TradingView
Third positive DSMC review backs EyePoint (EYPT) Phase 3 DURAVYU wet AMD trials - Stock Titan
Eyepoint Inc Announces Third Consecutive Positive Dsmc Recommendation for Phase 3 Wet Amd Trials for Duravyu - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
EyePoint: DURAVYU's Durability Could Drive Significant Upside (NASDAQ:EYPT) - Seeking Alpha
Adage Capital files amendment: 3,300,000 shares in EyePoint (EYPT) disclosed - Stock Titan
TradingKey - TradingKey
Liquidity Mapping Around (EYPT) Price Events - Stock Traders Daily
EyePoint Pharmaceuticals stock (US30233B1098): Trading at discount to fair value estimates - AD HOC NEWS
Mizuho Securities Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
Is It Too Late To Consider EyePoint (EYPT) After A 133% One-Year Surge? - simplywall.st
HC Wainwright Issues Pessimistic Forecast for EYPT Earnings - MarketBeat
Is EyePoint’s Revenue Slide and DURAVYU Cash Runway Altering The Investment Case For EyePoint (EYPT)? - simplywall.st
H.C. Wainwright Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
EyePoint, Inc. (EYPT) Stock Analysis: A Biotech Gem With 177% Potential Upside - DirectorsTalk Interviews
EyePoint Announces First Quarter 2026 Revenue Results - VisionMonday.com
EyePoint (EYPT) Reports Strong Q1 Revenue and Anticipates Key Tr - GuruFocus
RBC Capital Maintains EyePoint(EYPT.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
EYPT Maintains Rating by RBC Capital -- Price Target Lowered to $37 - GuruFocus
EyePoint 1Q Loss $84.8M >EYPT - Moomoo
[10-Q] EyePoint, Inc. Quarterly Earnings Report - Stock Titan
EyePoint (EYPT) Q1 2026 Earnings Transcript - AOL.com
MSN Money - MSN
Guggenheim reiterates Buy on EyePoint stock, cites trial progress By Investing.com - Investing.com India
RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating - marketscreener.com
A Quick Look at Today's Ratings for EyePoint(EYPT.US), With a Forecast Between $20 to $43 - Moomoo
EyePoint Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Number of shareholders of EyePoint, Inc. – LSX:A2QJRU - TradingView
Guggenheim reiterates Buy on EyePoint stock, cites trial progress - Investing.com UK
Eyepoint Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):